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Multiplex immunoassays confer several advantages over widely adopted singleplex immunoas-
says including increased efficiency at a reduced expense, greater output per sample volume
ratios and higher throughput predicating more resolute, detailed diagnostics and facilitating
personalised medicine. Nonetheless, to date, relatively few protein multiplex immunoassays
have been validated for in vitro diagnostics in clinical/point-of-care settings. This review article
will outline the challenges, which must be ameliorated prior to the widespread integration of
multiplex immunoassays in clinical settings: (i) biomarker validation; (ii) standardisation of
immunoassay design and quality control (calibration and quantification); (iii) availability, sta-
bility, specificity and cross-reactivity of reagents; (iv) assay automation and the use of validated
algorithms for transformation of raw data into diagnostic results. A compendium of multiplex
immunoassays applicable to in vitro diagnostics and a summary of the diagnostic products
currently available commercially are included, along with an analysis of the relative states of
development for each format (namely planar slide based, suspension and planar/microtitre
plate based) with respect to the aforementioned issues.
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1 Introduction
Over the past 20 years, the development of high-throughput
technologies for genomic and proteomic analysis has ush-
ered in a novel era of biomarker discovery, which has thus far
yielded numerous new markers, many of which maintain an
undefined pathophysiological significance and limited practi-
cal clinical application [1–3], whereas others are already bear-
ing a notable impact on disease diagnosis and therapy [4].
While contemporary singleplex ELISA formats are able
to accurately diagnose diseases whereby characterisation of
a single analyte is sufficient (i.e. HIV–1 p24); patient strati-
fication and monitoring of more complex, multifactorial dis-
eases such as cancers, graft-versus-host disease, autoimmune
and neurodegenerative diseases require the analysis of multi-
ple biomarkers in order to implement optimised therapeutic
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regimens [5]. Accordingly, validation of novel biomarkers and
their amalgamation into multiplex immunoassay panels con-
fers the attractive prospect of simultaneous measurement of
multiple analytes in a single patient sample, thereby min-
imising assay costs, time and sample volume while concur-
rently enabling progression monitoring and outcome predic-
tion to anticipate potentially severe sequelae or adverse drug
reactions. Moreover, the advent of multiplex technology com-
plements an ongoing progressive shift towards personalised
medicine with holistic, molecular fingerprinting of diseases
via the identification and characterisation of biomarker pro-
files to accommodate greater diagnostic resolution between
closely related disease phenotypes. For such reasons, it ap-
pears highly likely that multiplex immunoassays will con-
tinue to garner popularity and secure a mainstream role
in research and eventually clinical spheres. The subject of
this review will be an outline of the contemporary multiplex
immunoassay formats in tandem with a perspective of the
ongoing challenges that must be ameliorated prior to the
widespread integration of the technology into clinical set-
tings. Accordingly, the aim is towards clarifying the intricate
and intertwined technological issues in the hope of promot-
ing directives for future development.
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2 Historical perspective on immunoassay
development
Immunoassays such as singleplex/conventional ELISA for-
mats have assumed a ‘workhorse’ role in the highly sensitive
qualitative and quantitative detection of analytes within het-
erogeneous samples for over 50 years. Moreover, the advent
of hybridoma technology in the 70s as a means of gener-
ating monoclonal antibodies [6] has facilitated the genera-
tion of highly robust, antibody-based assays with a procliv-
ity for standardisation and automation. While multiplex and
singleplex ELISA adopt a common, ‘sandwich’ format (i.e.
capture antibody, sample addition and detection antibody),
the latter is typically developed upon addition of a colori-
metric enzymatic substrate. Contrastingly, multiplex ELISA
adopts chemiluminescent/fluorescent reporter systems, as
enzymatic reporters are chemically incompatible for simul-
taneous analysis of multiple localised targets. On this basis,
we adopt a terminology of ’immunoassay’ in lieu of ’ELISA’
throughout. The notion of immunoassay miniaturisation for
diagnostics was initially conceived in 1963 when J.G. Fein-
berg and A.W. Wheeler developed a ‘microspot’ technique as
a means of detecting autoimmune antibody and tissue anti-
gens, whereby thyroglobulin immobilised in a microspot on
cellulose acetate strips were incubated with serum from au-
toimmune thyroiditis patients [7] (Fig. 1). The presence of
autoantibodies in the sera resulted in the spontaneous pre-
cipitation of thyroglobulin in the microspot. The ability of
the technique to detect low levels of both the autoantibody
and its cognate antigen led the authors to propose that such
microspot assays ‘would have a particular advantage for rou-
tine use on clinical specimens because it is simple, sensitive,
objective, quickly carried out and read, requires but minute
quantities of serum and antigen, and provides a permanent
record for the case files’. Subsequently, in 1989, R. Ekins
devised the ambient analyte theory [8] postulating that minia-
turisation of immunoassays (i.e. reduction of the capture an-
tibody concentration) elicits an improved LOD. According to
the law of mass action concerning the behaviour of solutions
in dynamic equilibrium, only a diminutive proportion of the
total concentration of analyte molecules would be captured
on a spot composed of a reduced quantity of immobilised cap-
ture antibodies; thus, given ambient analyte conditions, the
total concentration of analyte in a sample would not alter sig-
nificantly despite the high affinity of the capture antibody in
conjunction with the low total analyte concentration. There-
fore,miniaturisation renders concentration dependency inas-
much that the quantity of captured analyte in the spot is rep-
resentative of the total analyte concentration in the sample.
A high overall sensitivity is achievable with miniaturisation
as analyte measurement is always conducted while retain-
ing the highest concentration per unit volume attainable for
the given sample, with decreased reaction times due to cur-
tailed diffusion distances. Taken together, Ekins outlined the
fundamental microarray multiplex technology principles and
envisioned their potential application in research and clini-
cal diagnostics. Historically these findings have influenced
the trajectory of multiplex immunoassay development. The
necessity of protein microarray technology for the identifi-
cation, quantification and functional analysis of proteins in
basic and applied proteome research has been accentuated
since the turn of the 21st century, in part due to a shift in
genomics and proteomics towards the analysis of gene and
cognate protein function frommore holistic perspectives, but
also by virtue of the fact that there is no absolute correlation
between mRNA expression levels and corresponding protein
expression. Furthermore, it is impossible to deduce the func-
tional state of a protein solely from its expression level; thus,
large-scale screening operations implemented by the post-
genomic era have thus encompassed applications ranging
from functional analysis of unknown genes to identification
of disease-related gene products, screening in drug discovery
Figure 1. Timelines charting the theoretical and practical milestones in the development of multiplex technology for suspension and planar
immunoassay formats. The first commercial suspension array was available before the first planar-based array [94–96].
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and clinical diagnostics. Notably, due to the proof of concept
afforded byDNAmicroarrays and the ongoing necessity to de-
velop high-throughput technologies facilitating the analysis
of proteome functionality, there has been a surge in the devel-
opment and refinement of multiplex protein immunoassays
(Fig. 2).
3 Commercially available multiplex
immunoassays
Several high-content protein microarrays for comparative
profiling are available commercially (Tables 1 and 2) [9–59],
however, of these, relatively few have been validated for in
vitro diagnostics (IVD) applications; moreover, despite the
theoretical multiplexing capacities of the platforms, com-
mercially available panels appear to only harness a fraction
of this capacity, seldom exceeding 20 individual analytes
[46, 60–62]. Contemporary multiplex immunoassay systems
may be divided into the two described formats: planar as-
says and microbead-based suspension assays (Fig. 3). The
planar format includes platforms such as the Mesoscale Dis-
covery Technology Platform (MSD R©) and the Q–PlexTM array
(Quansys Biosciences) whereby high-affinity capture ligands
are immobilised discretely on a solid phase, 2D support,
usually in a microtitre plate format, although multiplexed
assays on functionalised glass slides are also available. The
immobilised ligands are subsequently exposed to treatment
with the sample and probing with detection antibodies la-
belled with a reporter system. The suspension format in-
cludes platforms such as LuminexTM, Cytometric BeadArrays
and Bio–PlexProTM whereby high-affinity capture ligands are
immobilised discretely on fluorescently activated plastic mi-
crobeads and mixed with the sample in liquid phase. Subse-
quent addition of detection antibodies labelled with a reporter
dye enables high-resolution analysis of specific fluorescent
signal via flow cytometric methods. Notably, for both formats
a reciprocal approach known as RP protein array may also
be adopted, whereby sample material representing the pro-
teomic repertoire of the isolate source is bound to the array
surface and subsequently probed with antibodies specific to
the target components. However, in contrast to conventional
sandwich/capture-based assays, the heterogeneity of the im-
mobilised sample necessitates an imperative for validated,
highly specific antibodies to negate false-positive readouts
[45].
4 Development of multiplex
immunoassays
Generically, multiplex immunoassay development has been
considered in the context of two primary arenas: the detection
platform itself and the immunoassay chemistry. The initial
Figure 2. Number of publications published per year, as found within the PubMed database (sampling 1996–2013) using the following
keywords search parameters. Multiplex ELISA, multiplex immunoassay, multiplex array, microarray immunoassay, ‘or’ set of searches is
derived from accumulating the search terms above using a logical or to combine: (((((multiplex immunoassay) or multiplex ELISA) or
multiplex bead) or multiplex cytokine) or multiplex array) or bead immunoassay multiplex+ = ((bead) or (cytokine) or (ELISA) or (array) or
(protein) or (antibody) or (antigen) and immunoassay) and multiplex. Numbers were obtained by the PubMed build-in year count facility,
by downloads of CSV files for each search performed, after reviewing the returned papers. The year 2013 was chosen as a cutoff as current
year PubMed papers are still increasing each month at the time of writing.
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Table 1. Commercially available multiplex arrays suitable for a variety of clinical indications
Indication(s) Target Company Product Platform/format FDA
approved
Allergies Antibodies Phadia ImmunoCAP R©
ISAC
Planar array –
Autoimmune Antibodies INOVA Diagnostics QUANTA Plex R© Luminex +
Allergies Antibodies ImmuneTech MyAllergyTest Luminex +
Allergies (domestic
allergens)
Antibodies INDOOR Biotechnologies IgE–QBATM Luminex –
Autoimmune Antibodies Immucor BeadChipTM Bead array +
Autoimmune Antibodies Theradiag FIDISTM System Luminex +
Autoimmune, Infectious
Disease
Antibodies Zeus Scientific AtheNA
Multi–Lyte R© Test
System
Luminex +
Autoimmune, Infectious
Disease
Antibodies Bio–Rad Laboratories Bio–Plex R© 2200
Autoimmune
and Infectious
Disease Panels
Luminex +
Autoimmune Antibodies Whatman FAST Quant R© Planar array –
Multiple Proteins Myriad RBM Human MAPs Luminex –
Cardiovascular,
Infectious Disease
Antibodies
+ Proteins
Biome´rieux VIDAS R© range VIDAS +
Cardiovascular Proteins Alere Triage R© Cardiac
Panel
Triage –
Infectious Disease Antibodies Arrayit Corporation Pathogen Antigen
Microarrays
Planar array –
Infectious Disease Antibodies DiaMex Optiplex Borrelia Luminex –
Infectious Disease Antibodies Focus Diagnostics PlexusTM
HerpeSelect R©
Luminex +
Multiple Proteins Randox Biochip Array Planar +
Neurodegenerative
disorders
Proteins Innogenetics NV INNO–BIA AlzBio3 Luminex +
HLA typing Antibodies Gen–Probe LIFECODES range Luminex +
Acute Phase Protein
Profiling
Proteins R&D Systems Human Cytokine
Array Panel A
Planar array –
Multiple Antibodies
+ Proteins
RayBiotech Quantibody R© Planar array –
Acute Phase Protein
Profiling
Proteins Quansys Q–PlexTM array Planar array –
Cytokine Profiling Proteins Aushon Ciraplex R© Planar array –
Multiple Proteins Meso Scale Discovery MULTI–ARRAY
microplate
Planar array –
Cytokine Profiling Proteins QuantiScientifics, LLC A2 R© Multiplex
ELISA Human
Cytokine Panel
Planar array –
Multiple Proteins eBioscience FlowCytomixTM
Multiplex
Flow cytometry –
Cytokine Profiling Proteins BD Biosciences CBA Human
Th1/Th2/Th17
Kits
Flow cytometry –
Multiple Antibodies
+ Proteins
Illumina VeraCodeTM Luminex –
Assays that have progressed past pre-clinical validation studies and attained regulatory body approval for their clinical application are
designated with a ‘+’ in this table. Those that have demonstrated clinical viability and applicability in pre-clinical validation studies but not
demonstrated compliance with regulatory parameters are designated with a ‘–’ in this table but a ‘+’ in Table 2.
platform configured for high-throughput proteomic screen-
ing was the slide-based planar or ‘chip-based’ microarray,
offering the prospect of whole proteome analysis via a single
sample. According to the ambient analyte theory, planar im-
munoassays may exhibit a theoretical resolvable specificity
within the femtomolar range; however, few systems actu-
ally achieve such specificities in practise primarily due to
the physiochemical behaviour of the analytes in the sample
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Table 2. Commercially available multiplex arrays suitable for IVD, which have demonstrated clinical viability and applicability in pre-clinical
validation studies but not demonstrated complete compliance with regulatory parameters (at time of writing) are designated with
a ‘–’ in Table 1, but with a ‘+’ in this table
Company Product Validation Reference
Phadia ImmunoCAP R© ISAC + [9–13]
INDOOR Biotechnologies IgE–QBATM + [14–16]
Bio–Rad Laboratories Bio–Plex R© 2200 Autoimmune and Infectious Disease Panels + [17–21]
Whatman FAST Quant R© + [17,22,23,45]
Myriad RBM Human MAPs + [24–28]
Alere Triage R© Cardiac Panel + [29,30]
Arrayit Corporation Pathogen Antigen Microarrays – a)
DiaMex Optiplex Borrelia –
R&D Systems Human Cytokine Array Panel A + [31–34]
RayBiotech Quantibody R© + [35–41]
Quansys Q–PlexTM array + [42–45]
Aushon Ciraplex R© – a)
Meso Scale Discovery MULTI–ARRAY microplate + [17,45–50]
QuantiScientifics, LLC A2 R© Multiplex ELISA Human Cytokine Panel –
eBioscience FlowCytomixTM Multiplex + [51–55]
BD Biosciences CBA Human Th1/Th2/Th17 Kits + [56–58]
Illumina VeraCodeTM + [59]
Commercially available multiplex arrays that have demonstrated neither clinical viability/applicability nor compliance with regulatory body
approval parameters but nonetheless may theoretically be applicable for clinical applications are designated with a ‘–’ in this table and
Table 1.
a) Manufacturer claims validation, although no supportive published data are provided.
matrix, particularly the depletion of analytes within the vicin-
ity of the capturing spots resulting in a mass transport con-
trolled (as opposed to a kinetically controlled) reaction. Appro-
priate sample mixing may ‘reset’ the concentration gradient
of the analytes around the capture zones to ultimately increase
the sensitivity and efficiency of the immunoassay, although
such manipulation of small volumes is technically problem-
atic and, for IVDsettings,would likely require a highdegree of
integration between the immunoassay and a fluidics system,
highlighting the necessity for robust automation [63]. Despite
such issues, planar immunoassays are somewhat less suscep-
tible to cross-reactivity as capture and detection antibodies are
co-localised in precisely aligned spots and dispensed in mi-
croliter volumes in air onto an immobile solid phase. Appro-
priate buffers to ensure the viability of antibodies or proteins
deposited on the array surface during storage is an important
consideration. Successful immobilisation of hundreds of dif-
ferent proteins in their native conformation on single glass
slides represents a considerable technological challenge. Con-
tinuous flow microspotter systems and other advanced array
printing technologies [5] may minimise such issues but re-
quire specialised, non-standard laboratory apparatus which,
at least as of present, is unrealisable in a majority of clin-
ical and research settings. Nonetheless, planar immunoas-
says maintain the promise of easy integration into existing
IVD settings as they are relatively inexpensive and would be
simple and efficient to operate if fully automated, thereby
accommodating large-scale population screening (Fig. 4A
and B).
The origins of suspension immunoassay technology date
back to the 1970s when Horan and Wheeless [64] recog-
nised, as part of a review describing some of the diverse
applications of flow cytometry, that micro-particles harbour-
ing antigen could constitute a solid support for the capture
of blood-borne antibodies; moreover by adopting differen-
tially sized microspheres distinguishable by their light scat-
ter properties, several analytes may be detected simultane-
ously. Subsequently, in the 1980s and 1990s, this approach
was extended to include antibodies, DNA and lipids [65]. Ac-
cordingly, the development and application of suspension
immunoassays closely parallels that of flow cytometery as a
detection platform, whereby advancements in the latter (par-
ticularly the improvements in capacity to make sensitive and
multi-parameter fluorescence measurements at high speeds)
has been exploited for in vitro analysis of molecular inter-
actions on microspheres and for the analysis and sorting of
biological libraries in single cells. Currently, the suspension
immunoassay format constitutes the prevailing technology
for FDA-approved multiplex protein analysis in clinical set-
tings [66], chiefly for serumantibody profiling in patientswith
allergies, autoimmune or infectious diseases. Notably, its
success is attributable in part to its surmounting of some
of the issues faced by planar immunoassays, such as print-
ing and washing artefacts, post-hybridisation image analy-
sis, data normalisation andmass-transport limitations, which
are abrogated by the conduction of the immunoassay in
a liquid phase whereby agitation is readily executed. Addi-
tionally, suspension immunoassay platforms, being flow cy-
tometry based, are highly amenable to automation whereby
calibration and quantification are all automatically and
integrally performed. Furthermore, replacement of conven-
tional polystyrene bead suspension immunoassays (of which
C© 2015 The Authors. PROTEOMICS - Clinical Applications Published by WILEY-VCH Verlag GmbH & Co. www.clinical.proteomics-journal.com
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Figure 3. Multiplex formats in common use include planar-based assays or suspension-based assays. (A) Planar arrays can be produced
in two formats, either slide based or microtitre based. A common starting point for such assays, as with ELISA, would be a serum sample
extracted from blood (i). Unlike microtitre plate based formats, slide-based formats support numerous layouts whereby repeated or
individual assays composed of specific sets of antibodies are printed robotically upon the activated slide surface (ii). The sample matrix
is applied and discrete assays are spatially separated by a frame and gasket, whereby they may be subsequently treated as individual
microtitre wells, subject to blocking, washing, etc. Internal standards and replicates may be included also (C). Detection results from
application of a composite of specific secondary antibodies coupled to a chemiluminescent/fluorescent reporter systems (iv). Microtitre-
based immunoassays harbour regularly printed antibody sets within the confines of the wells of a standard (SBS format) protein-binding
plate (v). The plate may thus be treated akin to a conventional ELISA (i.e. blocking, incubation and washing followed by detection
with a set of reporter-conjugated detection antibodies). (B) Suspension immunoassays also have a common starting point – serum
sample extracted from blood (i). This assay employs thousands of micrometre-sized plastic microbeads infused with a single (or several)
chemiluminescent/fluorescent dyes and a functionally activated surface, prior to linking with a specific capture antibody. Numerous sets of
such beads are prepared, eachmaintaining separate capture antibodies according to the cognate analyte and a unique fluorescent signature
enabling identification (ii). The sample and a cocktail of all the requisite bead sets are thereafter combined. Sets of detection antibodies, all
of which are individually labelled with a single chemiluminescent/fluorescent reporter (separate from those contained within the beads) are
added upon completion of incubation andwashing stages (iii). Each bead thus accommodates a ‘sandwich’ consisting of the captured target
analyte and the cognate reporter-conjugated detection antibody (iv). Post-additional washing stages, bead analyte reporter constructs are
subject to analysis in a flow chamber implementing individual bead separation, whereby lasers excite the chemiluminescent/fluorescent
reporters and emitted light is collected by a series of detectors for quantitative analysis (v).
laboriously necessitated several manual washes to prevent
clogging) with magnetic bead based immunoassays enabling
separation during washing steps has also significantly im-
proved the automation capacity of suspension immunoassays
within the past 5 years (Fig. 4C) [67]. Nonetheless, while these
assays have a high theoretical multiplexing capacity (up to
100-plex) – a desirable feature for comprehensive disease pro-
filing in clinical settings – in practice, cross-reactivity of cap-
ture and/or detection antibodies may compromise readout
viability. The susceptibility of multiplexed sandwich/capture-
based assays in a liquid phase to cross-reactivity increases
quadratically with the number of targets [68]; thus, if anti-
body reagents are altered or additional biomarkers are added
to the panel, the power of the assay may be undermined and
the entire optimisation process must be repeated. However,
perhaps the most tangible barriers to integration of suspen-
sion immunoassays into routine IVD settings are those im-
posed by the expenses and technical demands of operation
(i.e. maintenance costs and competency requirements in flow
cytometry of clinical laboratory staff).
5 Validation of multiplex immunoassays
The Clinical Laboratory Improvement Amendments (CLIA),
Food and Drug Administration (FDA), MHRA (Medicines
and Healthcare Products Regulatory Agency) and United
Kingdom Accreditation Service (UKAS) as well as other
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Figure 4. Radar plots depicting the developmental stage of components related to multiplexed assay systems. Each segment represents
one of the cardinal, inter-related requirements associated with validation of multiplex immunoassays for routine diagnostic application.
(A) Planar, microtitre plate based immunoassays; (B) glass slide based immunoassays and (C) suspension bead based immunoassays.
Accordingly, progress/research towards resolution of a particular aspect results in the corresponding segment filling outwards from the
centre, where maximum segment coverage represents a satisfactory standard for routine application in point-of-care/diagnostic settings. A
complete fill for all segments would represent an exacting qualification of an immunoassay format for unanimous integration into routine
point-of-care/diagnostic settings.
regional regulatory bodies require validation of novel ormodi-
fiedmultiplex assays prior to their enlistment in routine clini-
cal diagnostics for the generation of legitimate patient results.
Despite the fundamental requirement to validate these tech-
nologies on the basis of their demonstration of an acceptable
level of performance and robustness, specifically according
to metrics such as inter- and intra-assay reproducibility, an-
alytic sensitivity and specificity, whilst addressing LOD and
LOQ and reportable reference ranges/quality control stan-
dards. Currently no standardised regulatory guidelines for
the validation of multiplex biomarker assays exist [69]. Device
clearance or approval typically rests on the capacity of the
sponsor to provide analytical and clinical data demonstrating
that device performance is ‘functionally equivalent’ to that of
an alternate and well-established technique thereby inferring
adequacy with regard to its intended utility [70]. While this
is cogent when comparing the reliability and practicality of
a technique with similar chemistry and reaction dynamics,
it presents complications for techniques with clear differ-
ences in their operating principles. Furthermore, validation
continues into clinical practice andmust be continually mon-
itored to ensure an assay operates as expected and achieves
the intended results. In clinical practice, validation includes
proficiency testing, assessment of employee competency, in-
strument calibration and correlation with clinical findings.
Taken together, it will likely be difficult for clinical laborato-
ries both to validate these assays on their individual analytical
platforms and to demonstrate clinical relevance by perform-
ing large-scale preclinical/clinical studies, whichmay need to
involve multiple laboratories [69]. Consequently, establishing
a standardised evaluation paradigm should help ensure the
highest level of performancewithin and across laboratories so
that the tests provide patients with the most accurate results.
Quality control materials are not well developed for multi-
plexed protein immunoassays, and algorithms for interpret-
ingmultiplex quality control data are also needed [66] (Fig. 5).
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Figure 5. Pie chart representing relative preva-
lence of validated commercially available mul-
tiplex assays according to clinical application.
Please note that most of these assays are cur-
rently validated for research use only, implying
that they have not been validated to specific FDA
or other national/international clinical standards.
The largest numbers of commercially available
assays are for autoimmunity and allergy and cy-
tokines/chemokines.
5.1 Biomarker validation
Prior to the inclusion of a particular biomarker into a multi-
plex panel adopted for routine diagnostics, a developmental
course commencing with its origination and culminating in
its clinical validation will have transpired. The marker must
demonstrate its correlation with specific pathophysiological
processes and clinical endpoints, as well as diagnostic repro-
ducibility and accuracy, given the analytical method. Either or
both of these fundamental prerequisites may present barri-
ers to the clinical validation of amultiplex assay. For example,
hundreds of biomarkers have been identified (or proposed)
for complex diseases such as cancer, yet only a relative mi-
nority are clinically qualified, with themajority bearing either
unknown or incompletely characterised clinical significance.
Others, while theoretically suitable, may not exhibit consis-
tent and/or sufficient expression to warrant inclusion as an
assay modality. Ideal candidates for multiplex recruitment
would be markers whose qualitative and/or quantitative ex-
pression is unique to the disease, however, particularly in the
case of cancer, identifying truly specific markers has been
somewhat problematic. Many of the markers that were previ-
ously deemed to be ‘tumour specific’ such asMAGE–A3, have
since been shown to occur in healthy tissue (albeit diminu-
tively) and those that are truly specific (i.e. abnormal products
of ras and p53 genes) are in their own right common to sev-
eral cancers and thus do not constitute a differential basis for
different forms (i.e. rarer subtypes) of a single cancer.
The technical validation of a biomarker within the context
of an assay is a complex process that is interdependent on all
facets of the respective analyticalmethod including assay sen-
sitivity, specificity, reliability and reproducibility as well as the
nature of the biological sample and its integrity [71]. Speci-
ficity corresponds to the ability of the analytical method to
decisively distinguish the target biomarker from structurally
similar components within the same sample. Selectivity cor-
responds to the extent of analytical interference posed by ir-
relevant sample components. Reliability and reproducibility
determine the overarching precision of the analyticalmethod.
The nature of the samplemust also be considered with regard
to the locations of expression and distribution of the respec-
tive marker; the most appropriate sample for a given marker
would ideally accommodate sufficient analyte concentrations
with minimally invasive accessibility (i.e. urine, sputum, fae-
ces, saliva, serum, plasma or whole blood). Accordingly, the
physiological source(s) of a marker may also influence its
validation within the context of a multiplex immunoassay as
evidenced by the feasibility of obtaining the sample. Should
the analytical method exhibit sufficient sensitivity, then the
choice of sample is determined by the ease of sample collec-
tion and analysis.However, if sensitivity constitutes a limiting
factor and measurement of the marker in the specified bio-
logical fluid is problematic, then the sample type is selected
according to marker concentration regardless as to whether
this presents as a greater challenge for sample collection and
preparation [71]. The cardinal challenge facing biomarker val-
idation is characterisation of a marker, which is sufficiently
present in a minimally invasively acquired and stable sample
as so to be readily detectable by all multiplex immunoassay
formats with variances in specificity and dynamic range and
most importantly of all: reliably correlates (either individually
or concomitantly) with a clinically meaningful endpoint.
5.2 Standardisation of immunoassay design and
quality control (calibration and quantification)
On account of their ability to measure several analytes si-
multaneously, multiplex immunoassays present consider-
ably more quality control hurdles compared to singleplex
arrays [72]. Despite the necessity for extensive and trans-
parent quality control standards in IVD and point-of-care
(POC) settings, implementation into multiplex immunoas-
says is still underdeveloped thereby presenting a major and
uncompromising obstacle to widespread application of the
technology in clinical settings. This is primarily due to tech-
nicalities and discrepancies in immunoassay design; firstly
the generation of robust, meaningful calibration curves for a
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panel of heterogeneous markers under a common, localised
set of conditions (i.e. a ‘one size fits all’ problem). A piv-
otal phase in immunoassay development includes adjusting
calibration curves so as to reflect the physiological ranges
for each marker. The quantitative accuracy of multiplexed
assays hinges on the quality of the generated calibration
curves, which in turn is determined by appropriate curve-
fitting procedures, assay imprecision (CV), analyte recovery
and assay linearity (LOQs) [17]. Within IVD settings, the per-
formance of analytical tests is constantly monitored adopt-
ing well-characterised quality control materials containing
known concentrations of analytes; typically, for protein as-
says this encompasses reference samples of low,mediumand
high analyte concentrations at the commencement of a period
of usage [66]. However, selection of a single sample dilution
factor, which supports measurements within the physiolog-
ical ranges for each constituent marker on a panel, is often
unfeasible, necessitating the disjoining of the panel based on
circulating protein abundance. The failure of one constituent
marker to meet quality control specifications may necessitate
the rejection of results for all remainingmarkers on the panel
[72]. Optimisation of a communal format (which would also
facilitate automation) that functions aptly for each constituent
marker (e.g. sample dilution factor, capture/detection system,
incubation times andwashing steps) constitutes amajor chal-
lenge to standardisation of immunoassay design. Thus, the
probability of all assays within a multiplex panel simultane-
ously meeting quality control specifications is considerably
lower compared to that of a singleplex assay. The genera-
tion of viable quality control paradigms, which are applica-
ble across different analytical methods/platforms would be
advantageous for assessing inter-assay precision and ensur-
ing multi-centre quality assurance. However, such controls
would also require standardisation of immunoassay design.
Notably, quality controls are adopted for the establishment
of assay range and are therefore distinct from calibration
standards; thus, at the very least quality controls utilised to
validate an assay should be prepared adopting the cognate
sample type (and ideally derived from a discrete trial popula-
tion) [73]. Preparation of quality controls in buffers appears to
be suboptimal, as endogenous markers are not as adequately
represented compared to de facto samples, thus undermin-
ing accuracy and precision data reflecting assay performance.
However, merely adopting a biological sample by itself is in
no way sufficient as indicated by several studies reporting
higher inter-assay variability. Chowdhury and colleagues [46]
reported high intra-assay reproducibility and even compara-
ble inter-assay precision between Luminex and Mesoscale
Discovery technologies when measuring high target analyte
concentrations, but for measuring low concentrations, inter-
assay variation was variable and analyte dependent. Addi-
tionally, Bastarache and colleagues [74] reported acceptable
intra-assay variability but unacceptably high inter-assay vari-
ability when assaying identical patients’ samples on different
days adopting the Searchlight platform. Accordingly, gener-
ating a robust set of quality controls for clinical diagnostics
applicable to different assays/platforms presents a significant
technical challenge and currently quantitative comparison of
samples between different platforms is markedly inconsis-
tent. Currently, ascertaining quality control over several assay
cycles laboriously involves calculating representative metrics
for each standard curve per cycle, plotting the attained met-
rics and expected ranges on Levey–Jennings charts to define
outliers, excluding data from analysis based on quality met-
rics and identifying trends that require further investigation
[75]. A lack of robust multivariate quality control algorithms
and data rejection criteria for multiplexed immunoassays is
also problematic. This is primarily due to the fact that the
higher throughput of multiplex immunoassays necessitates
large sets of controls; for planar immunoassays this typically
encompasses spotted positive and negative controls, blank
areas, spotted detection conjugates, controls for non-specific
binding or cross-reactivity assessment andnormalisation [76].
Better statistical methods and quality control algorithms are
warranted to correct acquired data for analytical variability
in multiplex measurements. Encouragingly, standardisation
of data reporting, common analysis apparatus and mean-
ingful controls are developing under the Microarray Quality
Control Project for genetic testing to enhance statistical con-
fidence in the consistency and reliability elicited by platforms
analysing gene expression [72]. Initiatives for implementing
sustainable reference standards required for performance val-
idation efforts and quality control are progressing and trans-
lational application of similar initiatives for multiplexed pro-
tein immunoassays would be constructive. Taken together,
the emerging picture illustrates the interdependency of all as-
pects of multiplex development; for example, markers must
be amenable to assembly into panels under a set of com-
mon conditions to support comparison with each other plus
a robust set of calibration and quality control standards. Thus,
biomarker validation and quality control are intricately linked
at this stage in time.
5.3 Availability, stability, specificity and
cross-reactivity of reagents
Arguably the greatest impediment to integration of multiplex
immunoassays into IVD settings as of present is the avail-
ability of high quality (i.e. stable and specific) antibodies to
generate reliable output data and minimise cross-reactivity
[77]. This encompasses a range of manufacturing challenges
from the generation and characterisation of capture ligands,
antibody immobilisation chemistry, variability in the assay
manufacturing process and sample/reagent-derived cross-
reactivity. Conventional multiplex sandwich immunoassays
are conducted by incubatingmicrobeads or amicroarray with
a biological sample, followed by the addition of a mixture of
detection antibodies, with the premise that each antibody will
bind its cognate target analyte secured by the corresponding
capture antibody. Thermal or mechanical agitation ensures
that each reagent component encounters its target. It also
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results in combinatorial interaction of each detection anti-
body with all other analytes, capture antibodies and other
detection antibodies thus enhancing opportunities for cross-
reactivity [77]. Accordingly, suspension immunoassays are
theoretically more susceptible to cross-reactivity as mi-
crobeads circulating in a fluidic phase facilitate cross-linking
between protein components. Cross-reactivity may compro-
mise assay performance by reducing the LOD thus increas-
ing the probability of misrepresentative results. The quality
and reproducibility ofmultiplex immunoassays hinges on the
availability of highly specific capture ligands to bind tightly
to target analytes. However, predicting high-affinity interac-
tions between proteins is complex due to the hydrophobicity
and heterogeneity in size of the constituent amino acids.
Currently, monoclonal antibodies generated by classical hy-
bridoma techniques constitute the most widely utilised cap-
ture ligands [66]. Large-scale production and characterisation
of affinity, specificity, cross-reactivity and kinetic parameters
(namely association and dissociation rates) are labour- and
cost-intensive processes hindering validation; furthermore,
antibodies validated for singleplex assays may exhibit cross-
reactivity when adopted in a multiplex format, indicating a
necessity for application-specific validation of antibodies.
Antibody chemistry must also be considered in the con-
text of immobilisation for the purposes of maintaining im-
munoassay accuracy and reproducibility. Antibodies are rela-
tively stable in comparison to other proteins yet evenminimal
denaturation may expose hydrophobic regions predisposing
non-specific binding and potentially altering the lower LOD.
Generically, optimal antibody immobilisation chemistry ne-
cessitates the retention of a high affinity for the target analyte,
a high S/N and low variability between produced lots. Spe-
cific immobilisation parameters affecting the performance of
planar immunoassays include total antibody binding capac-
ity, size and morphology of antibody spots, background sig-
nal, LOD and printing reproducibility within and over multi-
ple immunoassays. For suspension immunoassays, standard
immobilisation protocols such as the adoption of surface im-
mobilised protein molecules recognising specific antibody
domains, chemical modification of carbohydrate residues in
the Fc regions or surface activity towards free thiol groups
may conceal epitopes containing extensive lysine or arginine
residues thereby resulting in failure of an antibody to consis-
tently recognise its cognate target analyte. Accordingly, the
surface chemistry formultiplex protein immunoassay formu-
lationwould ideally offer the following parameters: resistance
of the surface to non-specific adsorption; sufficient availabil-
ity of functional groups for ready and uncomplicated im-
mobilisation of target molecules; balanced bonding between
ligands and the immunoassay surface to ensure sufficient
stability yet minimal interference with the conformational
structure while enabling regulation of orientation; a local
chemical microenvironment conducive to the retention of
immobilised ligands in their native conformation and finally,
highly specific linkage chemistry to abrogate the necessity of
pre-purification of ligands [78].
Variation in immunoassay manufacturing processes also
confers imprecision; for planar immunoassays, printing con-
stitutes the single greatest determinant of variability, whereas
for suspension immunoassays, discrepancies inmicrosphere
production principally account for signal variability, whereby
10–32% of measurement variability may be attributable to
inconsistencies in microsphere diameter per se [66]. For RP
protein array, in contrast to capture-based immunoassays, a
fundamentalmanufacturing consideration is the heterogene-
ity of an immobilised sample and thus the absolute require-
ment for validated, highly specific antibodies to eliminate
false-positive signals. Taken together, the requirement for
complex antibody cocktails (both bead/slide associated and
reporter conjugated, all of which must be highly specific and
sensitive to attenuate cross-reactivity within the sample set)
in conjunction with lagging quality control standards will
likely remain the foremost limitation to extensive multiplex-
ing and IVD integration for some time. Given the limita-
tions of antibodies, evaluation studies for alternative capture
ligands including engineered protein and nucleic acid scaf-
folds are ongoing; aptamers are one such candidate, which
like antibodies possess target recognition features with the
capacity to distinguish between protein isoforms and con-
formations. Other approaches include refinement of the im-
munoassay chemistry itself; a recent and elegant approach by
Frampton and colleagues [5] was the conception of an aque-
ous two-phase system whereby phase separation promoting
polymers PEG and dextran were adopted to confine detection
antibody solutions in a fully aqueous environment to regions
where complementary capture antibodies were immobilised.
At length, continuing initiatives in the USA and Europe are
focused on improving the availability and quality of affinity
reagents, with the overarching aim of devising standardised
collections of comprehensively validated binding molecules
for proteomic analyses for the advancement of immunoassay
quality standards [79].
6 Considerations for embarking on
multiplexed immunoassays
When undertaking the use of either commercially available
multiplexed systems, or construction of in-house systems, it
is important to ensure the system has usable intra- and inter-
assay reproducibility. Inter-assay CVs of <20%, and usually
<10% are a reasonable expectation of most ELISA-based sys-
tems, and should be similarly expected of all assays within
a multiplex. Intra-assay CVs of <15%, and usually <10%
should be expected, however some commercial assays make
this difficult to assess due to the lack of appropriate numbers
of technical replications of each target within the multiplex
(i.e. if only duplicate features are used for each target). Studies
where bead and planar multiplex immunoassays have been
compared indicate that inter-assay CVs of between >2.8 and
<10% can be routinely obtained, however they are analyte
dependent [17].
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In our experience, there is little limitation on space for
planar multiplexed microarrays – the small size of individ-
ual features (spots) and the fact that arrays can be re-sized
easily, allows for substantial technical replication per assay.
We routinely use triplicate, quadruplicate or greater num-
bers of replicates for each target or control within the multi-
plex. This far surpasses usual practice in ELISA, where trip-
licates or sometimes only duplicate wells of each sample are
processed.
Building sandwich immunoassay multiplexes from
scratch would necessitate cross-testing the entire multiplex
assay against each target antigen alone to determine the extent
of any cross-reactivity seen. Specific issues to consider when
approaching the use of such multiplexed assays, whether in-
house manufactured or commercially obtained, are reviewed
below.
6.1 Data acquisition requirements
Access to a suitable high-resolution scanner or bead reader,
or availability of a scanning/reading service to which the
multiplexed assay can be sent once completed, is a key
priority. If sending processed multiplexes to a service, meth-
ods for stabilizing fluorescent signal should be addressed.
Commonly used red fluorescent reporters often show strong
ozone sensitivity, resulting in rapid signal loss if adequate
precautions are not taken [80]. Dyes based upon FITC can
show photo-bleaching, and suitable precautions to shield
from light prior to analysis should be addressed.
Choice of fluorescent wavelengths within the reporter is
beyond the researchers control for most commercial offer-
ings; however, choice of fluorophor is important, especially
for membrane- and nitrocellulose-coated glass planar arrays.
Nitrocellulose-coated surfaces have a high protein binding
capacity, but fluoresces intensely in the blue (488 nm)
to green (532 nm) spectrum when laser illuminated, lead-
ing to high background signals and low S/N. This autoflu-
orescence is diminished in the yellow (590 nm) and red
(635 nm) spectrum, and is virtually absent in the near in-
frared range (680–800 nm range). In addition protein aut-
ofluorescence, which varies between proteins, can be strong
in the blue to green region of the spectrum, as is often seen in
flow cytometric studies. Thus, red and infrared fluorophors
are preferred choices for reporter dyes. In contrast to nitrocel-
lulose, other surface treatments of glass to enhance protein
binding (such as reactive epoxy-silane or aldehyde functional-
isation) generally give low fluorescence, but also have a lower
binding capacity. For bead-based assays, fluorophor choice is
often dictated by the analyser’s capabilities (flow cytometer or
dedicated machine).
6.2 Dynamic range of readings
Analysis of conventional ELISA-based assays is usually by op-
tical absorbance readings per well, using a plate spectropho-
tometer; this gives a range of 0–3.5 (possibly 4) optical density
units, dependent on the reader. Far greater dynamic range
can be achieved using fluorescent or luminescent techniques
for ELISA, necessitating the use of black- or white-walled
microtitre plates to avoid light spill between wells. Equally,
luminescence or fluorescence is method of choice, over col-
orimetric detection, for planar arrays and fluorescence is the
only practical choice for bead-based systems. Both techniques
can deliver dynamic ranges extending over five orders ofmag-
nitude, dependent upon the detection system’s sensitivity.
Since these methods result in light output being converted
to a digital signal, the maximum signal depends upon the
bit depth of the detection system: 8 bits gives 256 levels;
16 bits, 65 536 levels and 24 bits 16 777 216 levels. It is there-
fore important to know what the data acquisition hardware
is capable of in order to avoid limiting signal range unneces-
sarily. Currently, 12 and 16 bit/pixel scanners represent the
mainstream technology, with some 24 bit scanners beginning
to appear on the market.
Even within available scanners for multiplex immunoas-
says, software and hardware capabilities are important con-
siderations. For critically sensitive planar microarray-based
assays, a scanning system that can average or additivelymerge
two or more scans of the same array can be highly beneficial.
Digital noise in such systems is random, within the design
of the optical detector’s specification. Thus, averaging several
images of the same array can lower background signal sig-
nificantly, thereby improving low range detection limits of
real signal. Optical resolution is also important – higher res-
olution imaging leads to an increased number of pixels per
feature, aiding quality control measurements and enabling
better alignment and identification of features.
Similarly for bead-based systems, dynamic range within
the bead detector’s optical path is critical to support good bead
cluster separation, and to support a wide dynamic range for
the assay itself. PMT settings have the potential to signifi-
cantly affect the dynamic range and assay linearity [81].
6.3 Quality control
Unlike ELISA-based assays, where an aberrant signal in a
single well cannot be assigned to a particular problem with
that well (i.e. failure to coat, uneven coating, bubbles or con-
tamination with debris, etc.), both planar and bead multiplex
systems support improved quality assessment.
6.3.1 Planar multiplex assay quality control
For planar arrays, high-resolution imaging supports consider-
able additional quality control information.Given appropriate
software (we routinely utilise Molecular Devices Genepix Pro
software), alignment of the data grid (i.e. where the arraying
robot thinks the spots are) with the actual image then allows
the software to locate the outline of each spot. Subsequent
analysis provides numerical data including feature diameter;
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circularity (100 being a perfect circle); pixel number in the fea-
ture; mean, median and summative pixel intensities within
the feature and for local background signal; percentage of pix-
els, which are saturated in the feature; percentage of pixels
above 1 and 2 standard deviations for the local background of
that feature; S/N and other, user defined data, dependent on
whether one or two colour fluorescent detection is used.
Mathematically defined exclusion of aberrant spots within
a microarray-based multiplex can therefore improve assay
CVs dramatically by removing replicates where the printing
of the feature itself, or subsequent treatment, has caused a
quality control issue. Exclusion criteria may include features
that show circularity scores <65%; features that are smaller
or larger than the mean diameter ± 2 SDs; features for which
<5% of the pixels are saturated; features in which the per-
centage of pixels above the background +1 SD is >60%.
Such screening flags the following for removal: poorly printed
features (i.e. a bad spot morphology, either not circular or
smaller/bigger than expected QC limits), saturated features
(no longer in the quantitative range, or with a fluorescent
speck of debris attached); very low-level signals. Comparisons
of median and mean feature pixel intensities can be used to
identify features where the coating of the spot is uneven (i.e.
such as forming a doughnut image due to inappropriate dry-
ing of the material on the array substrate).
It is not unreasonable to expect commercial suppliers to be
able to give such information, based upon testing of each par-
ticular batch of prepared multiplexed assays, if array based.
This would include expected lower LODs for each analyte, if
following the manufacturers guidelines with a control sam-
ple; this control sample should be available from the manu-
facturer. In addition, information detailing the expected di-
ameter of all features when imaged and data from a positive
control test to indicate expected feature quality, that is intra-
assay replicate CVs, etc., would be useful for comparison to
the user’s own results. Similarly, if manufacturing in-house
multiplexed planar assays, such quality control tests are an
integral part of the production process and during routine us-
age. Within our own production of multiplex protein arrays,
we expect spot diameter CVs to be below 5% for any given
target printed and circularity CVs <2.5% (<4% and <1.5%,
respectively, is routinely possible). Individual proteins within
features can affect surface tension of the spotting liquid and
give rise to small differences in spot diameter between dif-
ferent targets. However, diameter CVs of below 10% across
all targets on an array are common, with the individual target
replicates feature diameter CVs being <5%.
6.3.2 Bead-based multiplex quality control
Bead-based immunoassay multiplexes resolve the problem
of individual assay replicates, with many hundreds to sev-
eral thousand beads reporting on each captured analyte. Key
quality control features therefore reside in the ability to distin-
guish bead clusters based upon their inherent fluorescence,
variation in bead fluorescence, in relation to the bead reader’s
capabilities, can therefore make separation of high-level mul-
tiplexes a challenge. Like many fluorescent products, most
immunoassay beads are light sensitive, and should be appro-
priately protected to minimise variation in individual bead
and run-to-run fluorescence. In addition, if used as a one-
step immunoassay, bead-based systems can suffer from loss
of signal at high analyte exposure due to the long-established
hook effect [82]. The hook effect is a consequence of very
high analyte levels in a sample, whereby analyte binds to both
capture and detection antibodies, but saturating the binding
sites so that a capture analyte detection sandwich does not
form, resulting in decreasing signal with increasing analyte
concentrations. In common with other immunoassays, het-
erophilic antibody interference can also provide false-negative
and false-positive results [83]. Heterophile antibodies (those
that cross phyla in their reactivity) are present in up to 40% of
blood donors, and show low avidity and multispecies speci-
ficity [84, 85]. False positives arise where the heterophilic anti-
bodies bridge capture and detection antibodies in the absence
of analyte. False negatives occur where the capture or detec-
tion antibody is directly bound by the heterophilic antibodies
and blocked from binding to the analyte. The performance
of the system across a range of analyte concentrations spiked
into real samples is strongly recommended.
6.4 Local assay validation
Validation of the reproducibility and utility of the multiplex
system for the particular sample types anticipated is prudent,
as application to cell supernatants, tissue homogenates or
biofluids, depending on the assays performed, are likely to
cause significant differences in assay behaviour relative to
the manufacturers recommended usage.
For both commercial and in-house multiplex assays, devi-
ation from the standard sample type and operating procedure
would need careful reassessment of the control samples and
assay limits. Using samples with spiked-in targets in appro-
priate biofluids and determining accuracy of recovery is of
clear benefit in determining accuracy and precision of an
assay; however, the additional cost of performing such vali-
dation controls can be substantial. Particular immunoassay
targets, especially low abundance targets, often yield highly
variable results near the lower end of the sensitivity range.
Reasons for this variation may include heterophilic antibody
interference [83]; substantial sensitivity of the targetmolecule
to epitope loss due to denaturation; masking by other sample
components; degradation ormicro-heterogeneity of the target
within the sample.Given an otherwise standardised assay and
sample collection procedure, such interfering factors may be
beyond the researcher’s ability to control, although there are
methods for reducing heterophilic antibody interference [86].
While examples in the literature are rare, comparisons
between platforms have been reported. For instance Rhyne
et al. [87] performed a comparative study for amyloid plaque
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peptides and reported a Mesoscale Discovery-based triplex
assay producing intra-assay CVs of between >4 and <15%
dependent on the target; and inter-assay CVs were generally
<20%, but with certain targets giving high CVs (up to 80%).
In the same report, a triplexed luminex bead-based assay,
AlzBio3, gave intra- and inter-assay CVs of<20%, but poorer
accuracy with the supplied kit standards, with between 20
and 50% accuracy. Sensitivity of both platforms was reported
as satisfactory. The conclusion of the report is that in-house
testing and validation of commercial kits is recommended
prior to beginning a study, and that validation findings should
be published alongside the study findings. Further reports
include accuracy of a specific IgEmultiplex (the ISAC system;
a direct ELISA-type approach) that cites inter-assay CVs of
<10% for most antigen targets using a calibrator kit and
<22.9% for patient samples, with most being below 15%, but
up to 40% for a small subset of antigens [88,89]. In a further
study of sandwich-ELISA style microarrays for biodefense
toxin detection, the authors state that over 70 antibody pairs
were examined to produce a final set of 10 pairs that gave
good accuracy (75–120% recovery) and inter-assay CVs of
<20% [90].
As a final note on method validation, the FDA hand-
book, ‘Guidance for industry: Bioanalytical method valida-
tion guidelines’ [91] suggests that whilst 15% inter-assay CVs
are acceptable for most calibration tests, this range may be
relaxed to 20% CV at the lower limit of quantification.
7 Assay automation and the use of
validated algorithms for transformation
of raw data into diagnostic results
In addition to optimisation of immunoassay performance, ro-
bust and extensive automation in conjunction with analytical
software development is an inescapable prerequisite for full
integration of multiplex immunoassays into clinical diagnos-
tic settings for management of labour-intensive work flows,
variation between different instrumentation platforms and
amelioration of the necessity for high degrees of operational
competence. Given the theoretical throughput of multiplex
immunoassays, the analytical scope is also correspondingly
complex and must be carefully tailored according to required
diagnostic endpoints. For example, at the simplest degree
multiplex immunoassaysmay be adopted to generate a single
qualitative output such as the typing of a pneumococcal
species or evaluation of antibody titres for vaccination status
whereby a single result is expected; thus multiple positives
or a single negative result clearly equates to test failure. The
subsequent degree of complexity involves immunoassays
yielding patterns of possible outputs, all encompassed by a
defined disease category but withmarginally different clinical
implications. Therapeutic or prognostic validity established
on the basis of such immunoassays may vary according to
the individual analytes present, necessitating the disclosure
of some or all constituent immunoassay outputs as opposed
to a single qualitative result; this is typically the case with
autoimmune multiplex immunoassays. The greatest degree
of complexity subsists whereby individual outputs do not
bear any diagnostic significance, but the combined outputs
of numerous assays are processed by a pattern-recognition
algorithm to yield a single diagnostic result [92]. Such
analytical capacity presents the greatest challenge to clinical
implementation, but in turn entails the potential for detailed
disease phenotyping and the realisation of personalised ther-
apeutics for diseases such as cancer. One of the first clinical
diagnostic tests to adopt pattern-recognition algorithms was
a fully automatedHPLC drug screening system (the REMEDi
HS) produced by Bio–Rad in 1989. Over the intervening two
decades, a variety of interpretive tools have been recruited
for analogous exploratory studies with DNA microarrays,
including various clustering modes (i.e. self-organising
maps and hierarchical clustering) along with supervised
classification algorithms (i.e. K-nearest neighbours, support
vector machines and neural networks). Nonetheless, as with
all operational aspects of multiplex immunoassays adopted
for IVD, integration of pattern-recognition algorithms entails
corresponding regulatory burdens (i.e. FDA/MHRA, etc.,
approval), which must be contented prior to marketing.
Currently, the only FDA-approved pattern-recognition algo-
rithm adopted for proteomic microarrays is the K-nearest
neighbours classifier utilised by the BioPlex 2200 ANA
Screen assay. Encouragingly, however, once validated,
supervised classification algorithmic approaches are likely to
be extensively adopted for clinical applications. A significant
contemporary obstacle to algorithm validation is the devel-
opment of criteria for interpretation of combined quality
control data in conjunction with additional appropriate
criteria to verify the acceptability of the generated analytical
results. For example, whereby the immunoassay returns
outputs for all individual analytes within the predefined
limits established by the quality control material, there is
no issue. However, should one or more of the analytical
results for the quality control materials not fall within the
predefined control limits, it becomes less straightforward as
to how the total immunoassay should be managed. This at
length raises another issue as to the management protocols
of unrequested test data whereby the number of measured
analytes substantially exceeds the requirements as indicated
by a given clinical situation. Ironically, although multiplex
(particularly microarray) technology may ultimately demon-
strate cost efficacy for batch analysis, there is currently no
consensus as to how unrequested outputs should be stored
and/or reported. While the capacity to retrospectively report
unrequested analyte measurements may prove convenient
for investigatory studies whereby the availability of large
datasets for subsequent mining may be advantageous (i.e.
clinical trials); how such capabilities would translate into IVD
settings is unclear as the storage of unrequested patient test
data without disclosuremay feasibly raise legal issues in cases
whereby such results would significantly alter diagnosis or
treatment.
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8 Future directions
It is inevitable that many current singleplex assays will ul-
timately be replaced by multiplex alternatives. For both the
clinical and research immunology laboratory, multiplexing
immunoassays promise considerable savings in both time
and cost per assay. At the same time such multiplexing of-
fers more comprehensive analysis whether for research pur-
poses, differential diagnoses or monitoring of therapeutic
interventions. However as we have stated during this review,
widespread adoption of such technologies is dependent upon
the availability of robust, affordable analytical platforms and
validated multiplex-optimised antibody panels. For clinical
use, high-level automation is key to widespread future use,
whereas for the research laboratory, affordability of the ana-
lytical platform may be a prime consideration.
Multiplexed immunoassays that could be reduced to a
disposable, relatively cheap POC assay offer great potential
for improved health surveillance such as GP-led routine pe-
riodic health-care screening such as panoptic scanning for
potential autoantibodies, infectious disease and markers of
early onset chronic diseases such as diabetes, Alzheimer’s
disease and rheumatoid arthritis, requiring little in any user
skills, perhaps though microfluidics-based lab-on-a-chip type
approaches, and be able to extract a sample from perhaps a
single finger-prick of blood, possibly undertaking the separa-
tion of plasma from cellular components within the device
itself. Such future screening assays are also utterly reliant on
the availability of informative biomarkers.
Such POC devices might also be of great value for rapid
monitoring in intensive care units, or where speed of re-
sponse is critical, for instance in cases of suspected sepsis
[93]. The potential economic value to the healthcare system
of community clinic screening for common conditions to
identify early disease and thus initiate early treatment and
management should not be underestimated.
9 Conclusion
All multiplex immunoassay formats to date present a power-
ful and efficient means of charting the proteomic and phe-
notypic changes associated with a diverse range of patho-
physiological conditions. Moreover, since the advent of the
proteomic era, multiplex immunoassays now constitute in-
valuable tools for efficiently harnessing the wealth of infor-
mation available to expedite more holistic observations, im-
proved monitoring and treatment of disease in the future.
While the availability and implementation of commercialised
multiplex immunoassays for research applications is expand-
ing rapidly, incorporation of the technology within routine
clinical diagnostics is still several years away at least due to
the extent of operational and quality control issues such as
immobilisation strategies for samples/binding agents, cross-
reactivity and availability of standardised reagents, robust au-
tomation to minimise time and operational costs. Equally,
there is the issue of implementing appropriate algorithms
and directives for management of the informatics challenge
posed by systems capable of producing millions of assay re-
sults per day. Accordingly, future directives towards the real-
isation of routine multiplex immunoassays in IVD, besides
ongoing technological improvements, include improved re-
producibility and consistent reductions in the CV between
results from different immunoassays/platforms in addition
to new statistical developments to correct multiplex data for
analytical variability.
The authors have declared no conflict of interest.
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